Publication | Closed Access

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study

MedicineBiliary CancerPathologyPharmacotherapyCancer TreatmentOncologyRadiation OncologyCancer Research